Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by research analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating in a report released on Monday, TheFlyOnTheWall.com reports. The firm currently has a $390.00 price objective on the stock, up from their previous price objective of $342.00. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares after opening at $328.57 moved to $334.36 on last trade day and at the end of the day closed at $310.79. Company price to sales ratio in past twelve months was calculated as 14.60 and price to cash ratio as 44.27. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed a negative weekly performance of -5.68%.
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Peter Mueller sold 7,500 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $78.29, for a total transaction of $587,175.00. Following the completion of the sale, the executive vice president now directly owns 158,750 shares of the company’s stock, valued at approximately $12,428,538. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares fell -5.07% in last trading session and ended the day on $73.83. VRTX return on equity ratio is recorded as -38.00% and its return on assets is -18.00%. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) yearly performance is 41.33%.
Biogen Idec Inc. (NASDAQ:BIIB) said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix. Biogen Idec Inc. (NASDAQ:BIIB) shares moved down -8.22% in last trading session and was closed at $318.53, while trading in range of $313.08 – $355.00. Biogen Idec Inc. (NASDAQ:BIIB) year to date (YTD) performance is 13.94%.
NIKE, Inc. (NYSE:NKE) is engaged in the design, development and worldwide marketing and selling of footwear, apparel, equipment, accessories and services. NIKE is a seller of athletic footwear and athletic apparel worldwide. Nike Inc. (NYSE:NKE) weekly performance is -3.97%. On last trading day company shares ended up $75.21. Nike Inc. (NYSE:NKE) distance from 50-day simple moving average (SMA50) is -0.35%. Analysts mean target price for the company is $81.50.